PURPOSE: To evaluate the recovery rate and spontaneous in vitro maturation (IVM) of immature oocytes enclosed within or released from follicles during the processing of ovarian tissue prior to its cryopreservation. METHODS: Thirty-three oncologic patients who had not previously undergone chemo or radiotherapy underwent ovarian tissue cryopreservation (OTC) during natural menstrual cycles. Immature oocytes, enclosed within follicles or released during ovarian cortex processing, were collected and matured spontaneously in vitro for 48 h. Nuclear maturation was assessed every 24 h and the ability of the IVM oocytes to display a normal activation response following parthenogenetic activation was evaluated. The following outcome measures were also evaluated: disease, age, FSH, LH, E2, P4 and AMH serum levels, menstrual cycle day, recovery and spontaneous IVM and parthenogenetic activation rates. RESULTS: Oocytes recovered per patient were 3.3 ± 0.7 (1.8-4.7 oocytes, 95CI), regardless of the menstrual phase. The mean number of IVM oocytes per patient was 1.3 ± 0.2 oocytes (95CI: 0.8-1.8), regardless of menstrual phase (p = 0.86) and oocyte origin (p = 0.61). Forty-one percent of oocytes extruded the second polar body and formed one pronucleus after parthenogenetic activation. CONCLUSION: Twenty-one of the 33 women (63.6 %) requesting OTC produced at least one mature oocyte.
PURPOSE: To evaluate the recovery rate and spontaneous in vitro maturation (IVM) of immature oocytes enclosed within or released from follicles during the processing of ovarian tissue prior to its cryopreservation. METHODS: Thirty-three oncologic patients who had not previously undergone chemo or radiotherapy underwent ovarian tissue cryopreservation (OTC) during natural menstrual cycles. Immature oocytes, enclosed within follicles or released during ovarian cortex processing, were collected and matured spontaneously in vitro for 48 h. Nuclear maturation was assessed every 24 h and the ability of the IVM oocytes to display a normal activation response following parthenogenetic activation was evaluated. The following outcome measures were also evaluated: disease, age, FSH, LH, E2, P4 and AMH serum levels, menstrual cycle day, recovery and spontaneous IVM and parthenogenetic activation rates. RESULTS: Oocytes recovered per patient were 3.3 ± 0.7 (1.8-4.7 oocytes, 95CI), regardless of the menstrual phase. The mean number of IVM oocytes per patient was 1.3 ± 0.2 oocytes (95CI: 0.8-1.8), regardless of menstrual phase (p = 0.86) and oocyte origin (p = 0.61). Forty-one percent of oocytes extruded the second polar body and formed one pronucleus after parthenogenetic activation. CONCLUSION: Twenty-one of the 33 women (63.6 %) requesting OTC produced at least one mature oocyte.
Authors: Ingrid Segers; Ileana Mateizel; Ellen Van Moer; Johan Smitz; Herman Tournaye; Greta Verheyen; Michel De Vos Journal: J Assist Reprod Genet Date: 2015-08-08 Impact factor: 3.412
Authors: Patrick Imesch; David Scheiner; Min Xie; Daniel Fink; Erwin Macas; Raghvendra Dubey; Bruno Imthurn Journal: J Ovarian Res Date: 2013-04-18 Impact factor: 4.234
Authors: Fereshteh Safian; Mohammad Ali Khalili; Mojgan Karimi-Zarchi; Mehdi Mohsenzadeh; Sareh Ashourzadeh; Marjan Omidi Journal: Iran J Reprod Med Date: 2015-08